bioMérieux S.A. (BMXXY) Q1 2026 Sales/Trading Call Transcript
Summarize this article with:
SA Transcripts159.41K FollowersFollow5ShareSaveCommentsFollow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock newsPlay Earnings CallPlay Earnings Call bioMérieux S.A. (BMXXY) Q1 2026 Sales/Trading Call April 23, 2026 8:00 AM EDT Company Participants Aymeric FichetPierre Boulud - Chief Executive OfficerGuillaume Bouhours - Executive VP of Finance, Purchasing and Information Systems & CFO Conference Call Participants Odysseas Manesiotis - BNP Paribas, Research DivisionKavya Deshpande - UBS Investment Bank, Research DivisionAisyah Noor - Morgan Stanley, Research DivisionJan Koch - Deutsche Bank AG, Research DivisionNatalia Webster - RBC Capital Markets, Research DivisionCharles Pitman - Barclays Bank PLC, Research DivisionAnna Ractliffe - BofA Securities, Research Division Presentation Operator Welcome to the bioMérieux 2025 Third Quarter Sales Conference Call. The call will be structured in 2 parts. First, a presentation by bioMérieux Group management team. [Operator Instructions] I will now hand over to Aymeric Fichet, VP, Investor Relations. Please go ahead.
Aymeric Fichet Thank you. Good afternoon, good morning, and thank you for joining us to review the Q1 2026 bioMérieux sales performance. I'm online with Pierre Boulud, CEO; together with Guillaume Bouhours, CFO. Please note that this conference call will include forward-looking statements that may change or be modified due to uncertainties and risks related to the company's environment. Accordingly, we cannot give any assurance as to whether we will achieve this objective. I also remind you that today's call is being recorded and that a replay will be available on our website, www.biomerieux-finance.com. I will now hand the call over to Pierre and Guillaume, and then we will open the call to discussion and questions. Pierre? Pierre BouludChief Executive Officer Thank you, Aymeric. Good day to everyone. So let me start with a few general messages before I say a few words about the guidance. We have dealt with a pretty complicated environment in Q1 with a very weak Q1 respiratory epidemiology versus what we already knew was a strong Q1 '25